HarrowHROW
About: Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
Employees: 382
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0.34% less ownership
Funds ownership: 58.49% [Q4 2024] → 58.15% (-0.34%) [Q1 2025]
5% less funds holding
Funds holding: 165 [Q4 2024] → 156 (-9) [Q1 2025]
12% less repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 58
21% less capital invested
Capital invested by funds: $699M [Q4 2024] → $551M (-$148M) [Q1 2025]
23% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 30
33% less funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 2 (-1) [Q1 2025]
48% less call options, than puts
Call options by funds: $11.9M | Put options by funds: $22.7M
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Cantor Fitzgerald Steve Seedhouse | 133%upside $76 | Overweight Initiated | 11 Jul 2025 |
HC Wainwright & Co. Yi Chen | 84%upside $60 | Buy Maintained | 12 May 2025 |
Financial journalist opinion
Based on 17 articles about HROW published over the past 30 days
